The U.S. Food and Drug Administration has approved a label update for Rybelsus tablets 7 mg or 14 mg, allowing use as a first-line treatment option for adults with type 2 diabetes who have not previously taken a diabetes treatment, Novo Nordisk announced "This update removes a previous limitation of use that stated the medication should not be used as the initial therapy for treating patients with type 2 diabetes. Initially approved by the FDA in 2019, Rybelsus is the first and only GLP-1 analog in pill form and is indicated, along with diet and exercise, to improve glycemic control for adults with type 2 diabetes," the company said.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVO:
- California AG files suit against drugmakers, PBMs over insulin prices
- Novo Nordisk price target raised to DKK 1,100 from DKK 925 at JPMorgan
- Novo Nordisk added to Analyst Focus List at JPMorgan
- Novo Nordisk price target raised to $145 from $130 at Cowen
- Novo’s (NYSE:NVO) Wegovy is Boosting Stock Price by Reducing Weight